Cadila is not only a credible Indian pharma striving for a Covid solution, but on a longer time scale is an interesting watch in the large-cap space witnessing a significant transformation in product portfolio.
Primed by strong bets on complex pharma opportunities
Drug major Dr Reddy's Laboratories is recalling 1,752 bottles of generic heartburn medicine in the US after the American health regulator found quality issues with the product.
The company's tablets are available in 54 mg dose in bottle count size of 90, and 160 mg dose in bottle count sizes of 90 and 500
Experts feel there are only a handful of companies that could be considered for investment for the year 2020
According to a CNBC-TV18 report, Jefferies, in its research note, has said that the Form 483 issued by US Food and Drug Administration (US FDA) contains four repeat observations out of the total 11 observations.
The company on Friday told the exchanges that its Formulations Manufacturing Plant - 3 at Bachupally, Hyderabad had been inspected by the US FDA. It has been issued a Form 483 with 11 observations.
The global broking firm also observed that three products, Nuvaring, Suboxone & Copaxone will be major contributors over FY19-20. In fact, the EPS for FY20 could see an upside of 44 percent to Rs 210 if these products are introduced.
Say headwinds in US hit financials, highlight further risks in terms of remediation delays at its plants.
Cite positive news on the regulatory front, but pain for Duvvada plant may remain, they say.
Brokerages largely remain optimistic about the pharma major’s improvement in US business as well as reduced regulatory risks, while some also highlight the seriousness of US FDA’s observations at some of its plants.
Fourth quarter earnings from India Inc. along with the Reserve Bank of India’s policy stance on rates will decide the trend for the market in this week.
Sources told CNBC-TV18 that it has received interest from domestic and global companies for the sale.
SBI, Maruti, HDFC, BHEL and ITC are top gainers while TCS, Infosys, Wipro, Dr Reddy's and NTPC are losers in the Sensex.
The market has started 2017 on a flat note as the Sensex is up 55.14 points or 0.2 percent at 26681.60. The Nifty is up 19.10 points or 0.2 percent at 8204.90. About 334 shares have advanced, 72 shares declined, and 3221 shares are unchanged.
Axis Bank, Wipro, Coal India, Dr Reddy's Labs and Asian Paints are top gainers while Tata Steel, Reliance, Tata Motors and Bharti are losers in the Sensex.
Asian Paints, TCS, Bajaj Auto, M&M and Hero MotoCorp are top gainers while Dr Reddy's Labs, ITC, Lupin, Cipla and GAIL are losers in the Sensex.
Bharti Airtel, Hero MotoCorp, Adani Ports, Maruti and Dr Reddy's are top gainers while Axis Bank, ICICI Bank, Tata Motors, GAIL and Wipro are losers in the Sensex.
Dr Reddy's Labs, Axis Bank, Sun Pharma, Cipla and Maruti are top gainers while Tata Steel, GAIL, HUL, TCS and M&M are losers in the Sensex.
Asian Paints, HUL, SBI, Tata Motors and Maruti are top gainers while ONGC, Axis Bank, M&M, Wipro and Dr Reddy's are losers in the Sensex.
GAIL, ONGC, Cipla, Tata Steel and Reliance are top gainers while Coal India, L&T, Axis Bank, M&M and Dr Reddy's Labs are losers in the Sensex.
L&T, Reliance, M&M, Dr Reddy's and Sun Pharma are top gainers while Axis Bank, Infosys, Bharti, Tata Motors and Hero MotoCorp are losers in the Sensex.
The Sensex is up 323.91 points or 1.1 percent at 28831.33 and the Nifty is up 107.10 points or 1.2 percent at 8884.25. About 924 shares have advanced, 99 shares declined, and 32 shares are unchanged.
Tata Motors, Axis Bank, Tata Steel, Reliance and BHEL are top gainers while Infoys, Bharti Airtel, Adani Ports and Dr Reddy's Labs are losers in the Sensex.
TCS, Wipro, Maruti, Bajaj Auto and Dr Reddy's Labs are top gainers while ICICI Bank, L&T, Adani Ports, BHEL and Lupin are losers in the Sensex.